Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSanford Actinic Keratosis Policy Update | OpenPaye…
    Ask Trek AI about this page
    CurrentSanford Health PlanPolicy 26213

    Actinic Keratosis - Score

    Customize your policy alerts

    Sign up for sanford health plan Policy 26213 alerts

    Get alerted when Policy 26213 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step-therapy coverage for diclofenac sodium gel 3% used for actinic keratosis under Sanford Health Plan's Medicare Part D benefit. Coverage requires a prior trial of topical fluorouracil or topical imiquimod.

    Policy Summary
    PayerSanford Health Plan
    PolicyActinic Keratosis - Score
    Policy CodePolicy 26213
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionFor diclofenac sodium gel 3%, document a trial of either topical fluorouracil or topical imiquimod.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Affected product
    2Alternative topical therapies
    ZonisadeAdditional product
    1 stepGeneric therapy trial
    New starts onlyStep therapy scope

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    AllowedContinuation therapy

    Coverage Criteria

    Initial Therapy

    Coverage requires the following step-therapy criterion.

    Required prior therapy: Trial of either topical fluorouracil or topical imiquimod before diclofenac sodium gel 3%.

    Initial Therapy

    For new starts:

    New-start requirement: Trial of generic zonisamide capsule required.

    Step applies to new starts only

    Continuation Therapy

    Continuation therapy:

    Continuation exception: Approve for continuation of prior therapy.

    Initial Therapy Criteria

    Required Alternative Therapy

    Diclofenac sodium gel 3% requires prior trial of an alternative topical therapy.

    Alternative topical therapy trial

    • Trial of topical fluorouracil.
    • Trial of topical imiquimod.
    ref-style-placeholder

    Initial Zonisade Therapy

    Generic zonisamide trial: Trial of generic zonisamide capsule.

    Step applies to new starts only

    Continuation Criteria

    Continuation of Prior Therapy

    Prior therapy continuation: Approve for continuation of prior therapy.

    Required Therapy Steps

    StepRequired prior therapyCoverage target
    1Trial of either topical fluorouracil or topical imiquimodDiclofenac sodium gel 3%
    StepRequired prior therapyCoverage applicability
    1Trial of generic zonisamide capsuleZonisade; new starts only. Continuation of prior therapy may be approved.

    Documentation and Provider Actions

    Documentation Required

    Document Required Topical Therapy Trial

    For diclofenac sodium gel 3% for actinic keratosis, document a trial of either topical fluorouracil or topical imiquimod before requesting coverage.

    • Affected product: Diclofenac Sodium GEL 3%
    • Required alternative therapy: topical fluorouracil or topical imiquimod
    Step Therapy

    Alternative Topical Therapy Required

    Diclofenac sodium gel 3% is covered only after the member has tried either topical fluorouracil or topical imiquimod.

    • Coverage requires documentation of one qualifying topical therapy trial.
    • Qualifying options: topical fluorouracil or topical imiquimod
    Policy Summary
    PayerSanford Health Plan
    PolicyActinic Keratosis - Score
    Policy CodePolicy 26213
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionFor diclofenac sodium gel 3%, document a trial of either topical fluorouracil or topical imiquimod.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaRequired Therapy StepsDocumentation and Provider Actions
    Denial Risk

    Required Prior Topical Therapy

    Coverage for diclofenac sodium gel 3% requires a documented trial of either topical fluorouracil or topical imiquimod.

    • Do not submit diclofenac sodium gel 3% as the initial topical therapy when the required trial is not documented.
    • The trial may be with either topical fluorouracil or topical imiquimod
    Step Therapy

    Generic Zonisamide Trial for New Starts

    For new starts of Zonisade suspension, document a trial of generic zonisamide capsules. This step therapy requirement does not apply when the member is continuing prior therapy.

    • New starts: trial of generic zonisamide capsule required.
    • Continuation of prior therapy: approve; the new-start trial requirement does not apply.
    Prior Authorization

    New-Start Step Therapy

    A trial of generic zonisamide capsules is required before initiating Zonisade suspension for a new start. Continuation of prior Zonisade therapy is allowed.

    • New-start step therapy applies to Zonisade suspension.
    • Document the generic zonisamide capsule trial for new starts.
    • Continuation of prior therapy is permitted.